HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

[1]  J. Buchner,et al.  The HSP90 chaperone machinery , 2017, Nature Reviews Molecular Cell Biology.

[2]  F. Speleman,et al.  ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[3]  M. Loh,et al.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.

[4]  A. Look,et al.  BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines , 2014, Leukemia.

[5]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[6]  D. Neuberg,et al.  Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia , 2014, Leukemia.

[7]  R. Young,et al.  The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia , 2013, The Journal of experimental medicine.

[8]  G. Shapiro,et al.  First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[9]  Angela G. Fleischman,et al.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.

[10]  V. Sondak,et al.  Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma , 2013, Molecular Cancer Therapeutics.

[11]  C Shepherd,et al.  PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response , 2012, Leukemia.

[12]  Susan Lindquist,et al.  Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition , 2012, Cell.

[13]  Tony Taldone,et al.  Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. , 2012, Biochimica et biophysica acta.

[14]  V. Sondak,et al.  The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms , 2012, Clinical Cancer Research.

[15]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[16]  A. Ferrando,et al.  ETV6 mutations in early immature human T cell leukemias , 2011, The Journal of experimental medicine.

[17]  Eric Vangrevelinghe,et al.  Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.

[18]  K. Ross,et al.  HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. , 2010, The Journal of clinical investigation.

[19]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[20]  S. Lindquist,et al.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.

[21]  A. Melnick,et al.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.

[22]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[23]  E. Raetz,et al.  Molecular pathogenesis of T-cell leukaemia and lymphoma , 2008, Nature Reviews Immunology.

[24]  J. Brueggen,et al.  NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models , 2008, Breast Cancer Research.

[25]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[26]  R. Porcher,et al.  Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[28]  Rob Pieters,et al.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.

[29]  L. Chin,et al.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.

[30]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[31]  R. Mesa,et al.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. , 2005, Blood.

[32]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[33]  S. Korsmeyer,et al.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 , 2003, Nature.

[34]  R. Gelber,et al.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Whitesell,et al.  The stress response: implications for the clinical development of hsp90 inhibitors. , 2003, Current cancer drug targets.

[36]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[37]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[38]  S. R. Datta,et al.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.

[39]  G. Linette,et al.  Bcl-XL and Bcl-2 repress a common pathway of cell death , 1995, The Journal of experimental medicine.

[40]  R. Arceci.  Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia , 2012 .